A novel peptide–nucleotide dual vaccine of human telomerase reverse transcriptase induces a potent cytotoxic T-cell response in vivo
- 15 June 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (4) , 1090-1095
- https://doi.org/10.1016/j.bbrc.2007.04.056
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirusBiochemical and Biophysical Research Communications, 2006
- Getting to the Surface: A Link Between Tumor Antigen Discovery and Natural Presentation of Peptide-MHC ComplexesClinical Cancer Research, 2005
- Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen–Restricted Cytotoxic T CellsCancer Research, 2005
- Immunological monitoring of cancer vaccine therapyExpert Opinion on Biological Therapy, 2004
- Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigenEuropean Journal of Immunology, 2004
- On the road to immortality: hTERT upregulation in cancer cellsFEBS Letters, 2004
- Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumorsCancer Gene Therapy, 2003
- Mimovirus: a Novel Form of Vaccine That Induces Hepatitis B Virus-Specific Cytotoxic T-Lymphocyte Responses In VivoJournal of Virology, 2002
- Proteomic analysis of the mammalian nuclear pore complexThe Journal of cell biology, 2002
- Cells Process Exogenous Proteins for Recognition by Cytotoxic T LymphocytesScience, 1988